Lululemon Athletica Inc. (LULU) At $81.04 Forms Top; 8 Bullish Analysts Covering RedHill Biopharma Ltd. (RDHL)

Among 8 analysts covering RedHill Biopharma (NASDAQ:RDHL), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. RedHill Biopharma had 14 analyst reports since July 29, 2015 according to SRatingsIntel. The company was maintained on Thursday, June 15 by H.C. Wainwright. The rating was maintained by FBR Capital with “Buy” on Thursday, June 15. The stock of RedHill Biopharma Ltd. (NASDAQ:RDHL) earned “Buy” rating by Nomura on Tuesday, September 29. The company was downgraded on Tuesday, August 25 by TheStreet. TH Capital maintained it with “Buy” rating and $31 target in Wednesday, July 29 report. The stock has “Buy” rating by Roth Capital on Tuesday, November 14. The firm has “Buy” rating given on Monday, July 31 by Roth Capital. FBR Capital maintained it with “Outperform” rating and $25 target in Friday, February 24 report. As per Saturday, August 22, the company rating was upgraded by Zacks. On Tuesday, September 29 the stock rating was initiated by Northland Capital with “Buy”. See RedHill Biopharma Ltd. (NASDAQ:RDHL) latest ratings:

26/01/2018 Broker: Nomura Rating: Buy New Target: $18 Initiates Coverage On
14/11/2017 Broker: Roth Capital Rating: Buy New Target: $20.0 Maintain
06/10/2017 Broker: Seaport Global Rating: Buy New Target: $19 Initiates Coverage On

Lululemon Athletica Inc. (LULU) formed multiple top with $86.71 target or 7.00% above today’s $81.04 share price. Lululemon Athletica Inc. (LULU) has $10.97 billion valuation. The stock decreased 0.07% or $0.06 during the last trading session, reaching $81.04. About 1.38 million shares traded. Lululemon Athletica Inc. (NASDAQ:LULU) has declined 19.33% since March 2, 2017 and is downtrending. It has underperformed by 36.03% the S&P500.

Since February 12, 2018, it had 0 insider buys, and 1 sale for $211.00 million activity. 2.75 million Lululemon Athletica Inc. (NASDAQ:LULU) shares with value of $211.00 million were sold by Wilson Dennis J..

Analysts await Lululemon Athletica Inc. (NASDAQ:LULU) to report earnings on April, 4. They expect $1.27 earnings per share, up 27.00% or $0.27 from last year’s $1 per share. LULU’s profit will be $171.93 million for 15.95 P/E if the $1.27 EPS becomes a reality. After $0.56 actual earnings per share reported by Lululemon Athletica Inc. for the previous quarter, Wall Street now forecasts 126.79% EPS growth.

Among 40 analysts covering Lululemon Athletica Inc. (NASDAQ:LULU), 23 have Buy rating, 1 Sell and 16 Hold. Therefore 58% are positive. Lululemon Athletica Inc. had 180 analyst reports since August 18, 2015 according to SRatingsIntel. On Monday, August 7 the stock rating was maintained by RBC Capital Markets with “Buy”. On Tuesday, January 9 the stock rating was maintained by Bank of America with “Buy”. As per Friday, September 1, the company rating was maintained by Nomura. The stock of Lululemon Athletica Inc. (NASDAQ:LULU) earned “Buy” rating by SunTrust on Friday, February 2. On Tuesday, January 12 the stock rating was maintained by Credit Suisse with “Outperform”. The stock of Lululemon Athletica Inc. (NASDAQ:LULU) has “Neutral” rating given on Tuesday, January 12 by UBS. The firm has “Hold” rating given on Thursday, January 11 by Wells Fargo. Robert W. Baird maintained Lululemon Athletica Inc. (NASDAQ:LULU) on Monday, October 2 with “Buy” rating. As per Thursday, December 10, the company rating was maintained by Topeka Capital Markets. RBC Capital Markets maintained it with “Buy” rating and $6400 target in Thursday, July 6 report.

Investors sentiment increased to 1.2 in Q3 2017. Its up 0.24, from 0.96 in 2017Q2. It improved, as 29 investors sold Lululemon Athletica Inc. shares while 89 reduced holdings. 54 funds opened positions while 88 raised stakes. 105.19 million shares or 0.45% more from 104.73 million shares in 2017Q2 were reported. Moreover, Prelude Cap Mgmt Ltd Liability Co has 0% invested in Lululemon Athletica Inc. (NASDAQ:LULU) for 400 shares. The North Carolina-based Fincl Bank Of America De has invested 0.01% in Lululemon Athletica Inc. (NASDAQ:LULU). Swiss Bancorporation reported 377,955 shares. X Mngmt Llc invested 0.01% in Lululemon Athletica Inc. (NASDAQ:LULU). Piedmont Inv Ltd Liability owns 19,229 shares. North Star Investment Mngmt invested in 0% or 210 shares. Balyasny Asset Mgmt Limited Company reported 1.37M shares. Art Advisors Ltd Company reported 195,500 shares. Leucadia owns 55,797 shares. California Public Employees Retirement Systems has invested 0.02% in Lululemon Athletica Inc. (NASDAQ:LULU). Edge Wealth Management Ltd Llc owns 0% invested in Lululemon Athletica Inc. (NASDAQ:LULU) for 140 shares. Gulf Int Bancshares (Uk) Limited holds 35,127 shares. Whittier holds 220 shares. Franklin Resource holds 10,075 shares. Mackenzie Fincl owns 3,727 shares or 0% of their US portfolio.

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases, and cancer. The company has market cap of $134.29 million. The firm promotes two gastrointestinal products in the U.S., such as Donnatal, a prescription oral adjunctive drug used in the treatment of IBS and acute enterocolitis; and EnteraGam, a medical food intended for the dietary management under medical supervision of chronic diarrhea and loose stools. It currently has negative earnings. The Company’s clinical-stage pipeline includes TALICIA , an oral combination therapy for the treatment of Helicobacter pylori infection with successful results from a first Phase III study and an ongoing confirmatory Phase III study; RHB-104, an oral combination therapy for the treatment of Crohn's disease with an ongoing first Phase III study, a completed proof-of-concept Phase IIa study for multiple sclerosis, and QIDP status for nontuberculous mycobacteria infections; BEKINDA (RHB-102), a once-daily oral pill formulation of ondansetron with successful top-line results in a Phase III study for acute gastroenteritis and gastritis and an ongoing Phase II study for IBS-D; RHB-106, an encapsulated bowel preparation licensed to Salix Pharmaceuticals, Ltd.; YELIVA (ABC294640), a Phase II-stage, orally-administered, first-in-class SK2 selective inhibitor targeting multiple oncology, inflammatory, and gastrointestinal indications; MESUPRON, a Phase II-stage first-in-class, orally-administered protease inhibitor, targeting pancreatic cancer and other solid tumors; and RIZAPORT (RHB-103), an oral thin film formulation of rizatriptan for acute migraines, with a U.S.

The stock decreased 0.31% or $0.02 during the last trading session, reaching $6.42. About 58,610 shares traded. RedHill Biopharma Ltd. (NASDAQ:RDHL) has declined 9.09% since March 2, 2017 and is downtrending. It has underperformed by 25.79% the S&P500.

Free Email Newsletter

Enter your email address below to get the latest news and analysts’ ratings for your stocks with our free daily email newsletter:



 

Recent Posts